EUVIMEDEUVIMED entdecken
Open Access

Elevated LDL-C and Lipoprotein(a) Modify Alirocumab Effects on CAV

Kosei Terada, Kuniaki Takahashi, Kiran K Khush, Takeshi Nishi, Joshua W Knowles, Anette Skoda, Brandon Varr, Christopher Woo, Yasuhiro Honda, William F Fearon

JACC: Heart Failure · 2026-08 · 103284

DOI: 10.1016/j.jchf.2026.103284 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Heart Failure, 2026-08. Verfasst von Kosei Terada und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Stanford University, Stanford, California, USA; Stanford Cardiovascular Institute, Stanford University, Stanford…. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIDDK NIH HHS, NHLBI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tweet: In heart transplant recipients, alirocumab attenuated cardiac allograft vasculopathy progression only in patients with concomitantly elevated LDL-C and lipoprotein(a). Lipid phenotype–guided risk stratification may identify those most likely to benefit from PCSK9 inhibition after heart transplantation. #PCSK9inhibition #CAV #HeartTransplantation

Schlagwörter

Stichwörter der Autor:innen

PCSK9 inhibitioncardiac allograft vasculopathyheart transplantationintravascular ultrasoundlipid phenotype

Autor:innen und Institutionen

  • Division of Cardiovascular Medicine, Stanford University, Stanford, California, USA; Stanford Cardiovascular Institute, Stanford University, Stanford, California, USA.
  • Division of Cardiovascular Medicine, Stanford University, Stanford, California, USA; Stanford Cardiovascular Institute, Stanford University, Stanford, California, USA; Stanford Diabetes Research Center, Stanford Prevent…
  • Kaiser Permanente, Santa Clara, California, USA.
  • Division of Cardiovascular Medicine, Stanford University, Stanford, California, USA; Stanford Cardiovascular Institute, Stanford University, Stanford, California, USA; VA Palo Alto Health Care System, Palo Alto, Califor…

Förderung

  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • NHLBI

Zitieren

APA

Terada, K., Takahashi, K., Khush, K. K., Nishi, T., Knowles, J. W., Skoda, A., Varr, B., Woo, C., Honda, Y., & Fearon, W. F. (2026). Elevated LDL-C and Lipoprotein(a) Modify Alirocumab Effects on CAV. JACC: Heart Failure, 103284. https://doi.org/10.1016/j.jchf.2026.103284

Vancouver

Terada K, Takahashi K, Khush KK, Nishi T, Knowles JW, Skoda A, et al. Elevated LDL-C and Lipoprotein(a) Modify Alirocumab Effects on CAV. JACC: Heart Failure. 2026:103284. doi:10.1016/j.jchf.2026.103284

BibTeX
@article{Terada2026,
  author = {Terada, Kosei and Takahashi, Kuniaki and Khush, Kiran K and Nishi, Takeshi and Knowles, Joshua W and Skoda, Anette and Varr, Brandon and Woo, Christopher and Honda, Yasuhiro and Fearon, William F},
  title = {Elevated LDL-C and Lipoprotein(a) Modify Alirocumab Effects on CAV},
  journal = {JACC: Heart Failure},
  year = {2026},
  pages = {103284},
  doi = {10.1016/j.jchf.2026.103284}
}
Kostenlos starten →